Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.
McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP. · 2008
Read Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. by McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2600703.txt.
Introduction
McCowan and colleagues followed 2,080 women treated for breast cancer in Tayside, Scotland, in 2008 to see whether sticking with tamoxifen affects survival. Tamoxifen, taken for five years after surgery, cuts breast cancer deaths, but how many women complete the course and whether adherence matters were unclear. The team linked cancer records from 1993 to 2002 with cashed prescription records.
Of the cohort, 1,633 women were prescribed tamoxifen, with a median use of 2.42 years. Only 49 percent of women followed for five years were still taking it at five years. Median adherence was 93 percent of doses, but women below 80 percent adherence faced a higher death risk, with a hazard ratio of 1.10 in that comparison. Longer use was tied to better survival, strengthening over time.
Catalog record
| CREATOR | McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer By C McCowan, J Shearer, P T Donnan, J A Dewar, M Crilly, A M Thompson, T P Fahey Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6604758 ABSTRACT Increasing duration of tamoxifen therapy improves survival in women with breast cancer but the impact of adherence to tamoxifen on mortality is unclear. This study investigated whether women prescribed tamoxifen after surgery for breast cancer adhered to their prescription and whether adherence influenced survival. A retrospective cohort study of all women with incident breast cancer in the Tayside region of Scotland between 1993 and 2002 was linked to encashed prescription records to calculate adherence to tamoxifen. Survival analysis was used to determine the effect of adherence on all-cause mortality. In all 2080 patients formed the study cohort with 1633 (79%) prescribed tamoxifen. The median duration of use was 2.42 years (IQR=1.04–4.89 years). Longer duration was associated with better survival but this varied over time. The hazard ratio for mortality in relation to duration at 2.4 years was 0.85, 95% CI=0.83–0.87. Median adherence to tamoxifen was 93% (interquartile range=84–100%). Adherence <80% was associated with poorer survival, hazard ratio 1.10, 95% CI=1.001–1.21. Persistence with tamoxifen was modest with only 49% continuing therapy for 5 years of those followed up for 5 years or more. Increased duration of tamoxifen reduces the risk of death, although one in two women do not complete the recommended 5-year course of treatment. A significant proportion of women have low adherence to tamoxifen and are at increased risk of death. Tamoxifen is an important adjuvant therapy for patients with breast cancer (Osborne, 1998) and reduces the breast cancer mortality rate over 15 years by 31% in women with oestrogen receptor-positive early breast cancers. (Early Breast Cancer Trialists’ Collaborative, 2005) Tamoxifen (20 mg once daily) is recommended for patients for 5 years adjuvant therapy (Early Breast Cancer Trialists’ Collaborative Group, 2004) to provide maximum benefit (Fisher et al, 1996; Stewart et al, 1996; Burstein and Winer, 2000). Adherence to a prescribed medication can be defined as: ‘the extent to which a patient's behaviour … coincides with medical or health advice’ (McDonald et al, 2002). Non-adherence to prescribed medication for patients with chronic conditions is a major public health issue. The level of non-adherence reported by studies is large, up to 50%, and many studies have shown worse clinical outcomes associated with low adherence (DiMatteo, 2004). The literature for tamoxifen deals with three different aspects of adherence to medication. The first, duration of tamoxifen therapy has an effect on disease recurrence and mortality from breast cancer with 5 years being the recommended treatment period (Swedish Breast Cancer Cooperative Group, 1996; Fisher et al, 2001; Yood et al, 2008). A second closely related aspect of adherence is persistence or continuation of therapy where the period that a patient continues to take the medication before a pre-specified break in medication is measured. This differs from duration in that if a patient restarts therapy after a break of the specified length this additional use of medication is ignored. Several recent studies have reported non-persistence with tamoxifen therapy. The first reported cumulative non-persistence for tamoxifen in a cohort of 2816 women at 22.1% after 1 year and 35.2% at 3.5 years (Barron et al, 2007). The second followed 961 women over 5 years and found that 49% stopped taking their tamoxifen before the recommended 5-year treatment period (Owusu et al, 2008). An earlier study reported 17% of women aged 65+ years had stopped treatment within 2 years (Fink et al, 2004). However, none of these studies assessed the impact of failure to persist with therapy on mortality or the independent effect of non-adherence in patients taking tamoxifen. The last aspect of adherence to tamoxifen is whether the patients take the medication consistently on a daily basis as prescribed. A recent review concluded that this aspect of non-adherence to adjuvant medication may limit the efficacy of breast cancer treatment, although there was limited evidence for this (Chlebowski et al, 2006). Adherence to adjuvant tamoxifen during clinical trials is high, with reported levels of 94–100% (Fisher et al, 1994, 1996; Dewar et al, 1996). Community-based studies found that 23% of patients failed to take tamoxifen in 1 out of 5 days with adherence falling from 89 to 50% over 4 years (Partridge et al, 2003) and that deviations from prescribed tamoxifen therapy were common (Demissie et al, 2001). A small survey on self reported adherence in 53 women found that 62% acknowledged having missed at least one dose of tamoxifen in the previous 6 months, with 24% missing at least one dose per week (Murthy et al, 2002). These studies suggest that non-adherence to tamoxifen is underestimated and further understanding of the relationship to mortality is required. No previous study has examined the overall effect on all-cause mortality of duration of use, adherence to and persistence with tamoxifen either in the hospital or community setting. The aim of this study was to investigate adherence to tamoxifen for all women with breast cancer drawn from a defined geographical population in Tayside, Scotland. The objectives were to: Describe the duration of use, adherence to and persistence with tamoxifen in a geographically defined population of women. Investigate whether duration and adherence to tamoxifen influenced all-cause mortality after adjusting for important clinical and demographic factors. MATERIALS AND METHODS Identification of study cohort Women resident in Tayside registered with the Cancer Registry as having breast cancer or with an initial hospital admission for breast cancer from 1993 to January 2002 were identified. Only those women who were resident for the entire period of the study or until death were included. Patients who had prescribing or hospital admission records, an audit record and a Cancer Registry record within the study period comprised the population of interest. Every patient registered with a general practitioner in Tayside is assigned a 10 digit unique patient identifier, the Community Health Index number (CHI number) used in all NHS encounters. The CHI number, which includes the patient's date of birth, allows linkage of health-related datasets providing a unique resource combining information on dispensed prescribing with detailed clinical data at the individual patient level. Study covariates Date of diagnosis was recorded from either the Cancer Registry or the clinical audit records and age at diagnosis was then calculated. Duration of breast cancer was calculated from the date of diagnosis to the date of death or until 7 January 2002, which was the study cutoff point. Each patient had a Carstairs score (a measure of deprivation (Carstairs and Morris, 1990)) and subsequent category calculated based on their home postcode using census data from 2001. There were only two patients in Carstairs category 7, the most deprived grouping, and so categories 6 and 7 were grouped together for analysis. A Charlson's co-morbidity index, which included a category for presence of cancer, was derived for each patient using standard procedures and the ICD codes version 9 (Deyo et al, 1992) and 10 (Sundararajan et al, 2004) in the hospital admission records. The encashed prescribing records were also examined and the Charlson disease groups were flagged for patients who